In 2026, the seventh Mount Tai Value-Based Healthcare Awards, hosted by MedJ, gave their Drug Breakthrough Award to Eli Lilly’s tirzepatide injection (Mounjaro). It was the second consecutive year the award had gone to a GLP-1 class drug — the previous year’s winner was semaglutide, honored for “redefining the paradigm of obesity treatment,” in recognition of a category-defining breakthrough. This year, the prize went to the first GIP/GLP-1 dual receptor agonist, recognizing an upgrade within the same category. The year before its award, tirzepatide had topped the global drug-sales charts with USD 36.5 billion in annual revenue, earning it the label of “drug king.”
The Mount Tai Award defines its Drug Breakthrough category narrowly: an original drug newly approved for marketing in mainland China, already in clinical use, and aligned with the principles of value-based healthcare. The three conditions correspond, in turn, to accessibility, clinical utility, and worth.
Dr. Li Wang, Senior Vice President, Global, and Head of Eli Lilly’s China Drug Development and Medical Affairs Center
A Target Sidelined for Twenty Years
Tirzepatide’s story begins with a target that had been overlooked for two decades.
Incretins are a class of hormones secreted by the gut after eating, with the role of stimulating insulin release. The body produces two main ones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).
GLP-1’s trajectory is well known. From glucose-lowering to weight loss, it has underpinned the most successful class of metabolic drugs of the past decade. GIP’s trajectory has been quite different. Researchers noted early on that, in patients with type 2 diabetes, the insulin-stimulating response to GIP was nearly absent. As a target for diabetes treatment, GIP sat on the bench for more than twenty years.
The idea of combining a “failed” target and a “successful” target in a single molecule was tried more than a decade ago. One multinational pharmaceutical company advanced an early dual-target candidate into Phase II, where the data were unremarkable, and the program was shelved. The route came close to being abandoned.
Eli Lilly chose to keep going. The reasoning rested on a revised understanding of GIP. In healthy individuals, GIP’s insulin-stimulating potency actually exceeds that of GLP-1. GIP also participates in central appetite regulation and adipose tissue metabolism; the two targets act through different pathways, in a complementary way. Lilly’s approach was also somewhat counter-intuitive: rather than starting from a mature GLP-1 scaffold, the team modified the amino-acid sequence of native GIP, so that the molecule simultaneously acquired GLP-1 receptor activity. A fatty-acid side chain then extended its half-life to about five days, allowing once-weekly dosing.
A Phase IIb trial published in The Lancet in 2018 delivered a key signal: over 26 weeks, glycemic and weight-loss effects increased dose-dependently and did not appear to plateau. That signal later gave rise to the SURPASS and SURMOUNT clinical programs, which together enrolled tens of thousands of participants.
In May 2022, tirzepatide was approved in the United States. The target had become the foundation on which the next drug king was built.
From Numbers to the Disease Itself
Translating gaps in care into quantifiable, endpoint-level benefit is the essence of value-based healthcare. Tirzepatide’s evidence chain maps neatly onto that definition.
The first layer is diabetes. The SURPASS Phase III program showed that tirzepatide’s glycemic and weight-loss effects were superior to those of existing GLP-1 receptor agonists. In the monotherapy studies, more than half of patients in the highest-dose group brought their glycated hemoglobin (HbA1c) below 5.7% — the threshold for the non-diabetic range, meaning their glucose metrics had returned to pre-disease levels.
The second layer is body weight. In SURMOUNT-1, adults with obesity but without diabetes lost more than 20% of their body weight on average at 72 weeks, and about a third lost more than 25%. Previously, weight-loss drugs had typically produced reductions of 5% to 15%; the 20% mark had been considered achievable only by bariatric surgery.
The third layer is China-specific evidence. The Chinese registration study was published in the Journal of the American Medical Association (JAMA), enrolling participants across 29 centers nationwide. Weight loss increased in a dose-dependent manner, with efficacy trends consistent with those in the global trials. Chinese patients no longer have to rely on data from foreign populations to judge whether a drug is right for them.
The fourth layer is the move from intermediate markers to disease endpoints. Obstructive sleep apnea (OSA) affects nearly 1 billion people globally. Standard treatment relies on nocturnal positive airway pressure devices, and long-term adherence is often unsatisfactory. Tirzepatide is the first approved drug for obesity co-existing with moderate-to-severe OSA, drawing a previously device-dominated disease into the realm of pharmacotherapy. In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide has also been associated with a reduced risk of cardiovascular events — a population that has long faced persistent dyspnea and limited activity tolerance, and for which targeted treatment options have been scarce.
The evidence has its limits. In a cardiovascular outcomes trial enrolling more than 13,000 patients with a median follow-up of about four years, tirzepatide met the non-inferiority standard but did not demonstrate superiority. Another study showed notable weight regain after treatment discontinuation. Taken together, these two findings point to the same reality: obesity is a chronic disease that requires long-term management. Medication is a tool, not an endpoint.
A New Global Drug, at China’s Speed
Tirzepatide was approved in the United States in 2022 and reached China in May 2024 — a cross-border lag of two years. A decade ago, the comparable delay for the same kind of drug would have been eight to ten years.
The timeline kept moving. In July 2024, the long-term weight management indication was approved in China; by the end of that year, the drug had launched commercially. In June 2025, the indication for obesity with moderate-to-severe OSA was approved, putting Chinese patients in step with global use of this new treatment option. By the end of 2025, tirzepatide had been included in the National Reimbursement Drug List through negotiation, restricted to the type 2 diabetes indication, with effect from 2026. In February 2026, the monotherapy indication was approved, extending the type 2 diabetes treatment scenario further upstream. Within just half a year of reimbursement listing, the drug is now available at more than 12,000 designated medical institutions and pharmacies nationwide.
Behind this timeline sits a research-and-development system that has been running for years.
“China has been deeply involved in the global development of this drug,” Dr. Li Wang, Lilly’s senior vice president and head of the Lilly China Drug Development and Medical Affairs Center, told MedJ. “I often say that what global headquarters has, China has. For Lilly, China is not only one of the fastest-growing strategic markets — it is also a core battleground for delivering on our mission of accelerating access to innovative medicines for patients around the world, including in China. Lilly continues to push for Chinese and global participation in the same clinical evidence base, so that the benefits of innovation reach every patient.”
The numbers she shared: Lilly China has cumulatively participated in roughly 100 global studies, working closely with about 1,400 clinical research institutions across more than 30 disease areas. In 2024, Lilly announced an investment of about RMB 1.5 billion to upgrade its Suzhou plant and expand manufacturing capacity for type 2 diabetes and obesity innovative medicines; in March 2026, the company announced plans to invest a cumulative RMB 20 billion over the next ten years to expand its supply-chain capacity in China, including a locally based oral solid-dose production and supply system.
Li Wang has been a firsthand witness to this “shrinking lag” journey. She had seven years of clinical practice before earning her doctoral degree from Shanghai Medical University in 1999, then completed postdoctoral research at Harvard University before joining Lilly in 2001. Rising from clinical research physician to senior vice president, she has helped bring more than 40 new drugs and indications to approval in China. In public reporting, she has been described as someone who takes on “the difficult but right thing.”
Tirzepatide is a footnote to that description. The Chinese registration study has appeared in JAMA; Chinese centers are participating in global Phase III; the rhythm of approval in China has entered the global first tier.
Most patients will never perceive the existence of the R&D system. But what they can perceive is this: an innovative drug has arrived in China, and it has arrived faster than before.
A Value Worth Paying For
Li Wang pointed to an often-overlooked fact: “Obesity is an upstream cause of more than 200 diseases, yet many people still do not see it as a disease. If the payment logic only covers treating disease after it occurs, patients only receive support when complications appear, which is a more expensive choice for the individual and for society.”
She added that, as innovative treatments evolve, the long-standing unmet needs in obesity management are receiving more attention. Lilly has publicly taken a stance against the cosmetic use of its obesity drugs, stressing that the approved indications are for serious diseases that warrant medical intervention, and that the goal is to help patients access more standardized, evidence-based disease management.
That view is being absorbed into the system. The 2024 Guidelines for the Diagnosis and Treatment of Obesity issued by China’s National Health Commission has formally defined obesity as a chronic disease requiring standardized diagnosis and treatment. The medical consensus is in: managing body weight well is itself a way of reducing the burden of a long list of downstream diseases.
Translating that consensus into payment shows similar progress. Tirzepatide’s diabetes indication was added to the National Reimbursement Drug List through negotiation, with a substantial price reduction that meaningfully lowered the access barrier for patients with diabetes. The weight-loss indication currently requires out-of-pocket payment, which remains a notable expense for patients who need long-term therapy.
The opportunity for change lies in the accumulating evidence. The U.K. National Institute for Health and Care Excellence (NICE), in its 2025 technology assessment, judged tirzepatide’s cost-effectiveness estimates for type 2 diabetes to fall within a range that permits reasonable use of healthcare resources and recommended routine adoption; real-world studies have shown average weight reductions of about 15% with a year of regular use, complementing the picture beyond clinical trials; and China’s newly issued OSA diagnosis and treatment guidelines have already incorporated tirzepatide into treatment recommendations.
“We hope to work with all stakeholders to use robust pharmacoeconomic and real-world evidence to advance the conversation around investing in upstream health,” Li Wang said. “A drug’s value must ultimately be defined by patients’ long-term outcomes.”
Returning to the Mount Tai Award yardstick, tirzepatide’s breakthrough has two layers. Scientifically, it has revived a target once written off and pushed pharmacologic weight loss into a range previously thought possible only with surgery. In terms of value, it has provided the first set of high-quality evidence — from glycemic control and body weight to sleep apnea and heart failure — supporting the idea that obesity is a disease worth treating.
A single drug can do only so much. It cannot answer every question — how the burden of long-term medication should be shared, or how access to the weight-loss indication can be broadened. But it has turned those questions into evidence-driven ones. For value-based healthcare, that is the prerequisite for the conversation to begin.
“China’s new drug R&D is moving from following the world to defining the world, from running alongside to leading,” Li Wang said. “There is a plain saying in our industry: the purpose of developing a drug is to address unmet clinical needs. Turning that saying into verifiable evidence is what we most want to do.”
Now the GLP-1 wave is surging. And the understanding and systems for managing metabolic health are trying to keep up.